2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesis
2017
JAK inhibitors in dermatology: The promise of a new drug class
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAnti-Inflammatory AgentsAzetidinesClinical Trials as TopicDermatitis, AtopicDermatologic AgentsHumansJanus KinasesMolecular Targeted TherapyNitrilesPiperidinesProtein Kinase InhibitorsPsoriasisPurinesPyrazolesPyrimidinesPyrrolesSignal TransductionSkin DiseasesSulfonamidesVitiligoConceptsJAK inhibitorsSoluble inflammatory mediatorsNew drug classesUseful therapeutic strategyDifferent proinflammatoryAtopic dermatitisInflammatory mediatorsInflammatory dermatosesAlopecia areataDrug classesJanus kinase-signal transducerTherapeutic strategiesJAK inhibitionDermatologic therapyKinase-signal transducerTargeted therapeuticsActivator of transcriptionDermatologyJAK-STATInhibitorsPromising new classEarlier reportsInhibition